Thus, although inhibition of IL-1 is a great strategy to prevent progression of atherosclerosis, we need novel therapeutic targets for specific inhibition of IL-1 within the vascular wall to avoid systemic off-target effects on immune cells (47). This evidence concerns the gene IL1B and atherosclerosis.